The Clinical Value of Serum KL-6 Changes on Evaluating Disease Development in Different Diffuse Parenchymal Lung Disease
The Clinical Value of Serum KL-6 Changes on Evaluating Disease Development in Different Diffuse Parenchymal Lung Disease
Diffuse Parenchymal Lung Disease(DPLD) is a chronic progressive fibrosis lung disease that
 with a highly variable clinical process.Krebs von den Lungen-6 (KL-6) is a
 high-molecular-weight glycoprotein, classified as human MUC1 mucin, that is produced mainly
 by regenerating type II pneumocytes.Serum levels of KL-6 have been shown to be elevated in
 patients with DPLD and could predict progress, but unaware of the differential threshold. The
 objective of this study was to perspectively and sequentially monitor serum KL-6 levels in
 patients with different DPLD,then analyze its clinical value and find the differential
 threshold.
Subjects and Method: Recruiting different DPLD patients in our hospital between 2013 February
 and 2016 October, including polymyositis/dermatomyositis related interstitial lung disease
 (PM/DM-ILD), rheumatoid arthritis related interstitial lung disease (RA - ILD), interstitial
 pneumonia with autoimmune features(IPAF) and idiopathic pulmonary fibrosis(IPF), following up
 for enery 3 to 6 months. Once condition deteriorated, patient could return at any time if
 necessary according to our clinical physician judgment. Tumor markers，pulmonary function
 test(PFT); chest thin-section CT examination and CT scores; serum KL-6 levels were acquired
 in all patients at baseline and follow-ups. Serum KL-6 was measured on LUMIPULSE G
 System(FUJIREBIO, JAPAN) by chemiluminescence enzyme immunoassay. All follow-up patients will
 be respectively divided into improved,stable and deteriotated group according to the official
 ATS/ERS statement.

 Inclusion criteria: (1)patient with PM/DM-ILD, RA-ILD, IPAF, IPF.The diagnosis of patient
 were according to the official ATS/ERS statement and the American College of
 Rheumatology/European League standard;(2)18 to 80 years old.

 Exclusion criteria: (1)conbination with pulmonary tubenculersis,pulmonary
 infection,tumor;(2)no serum KL-6 or pulmonary function test or chest thin-section CT
 examintion ;(3)patient with severe hepatic and renal dysfunction,heart disease or receiving
 hemodialysis treatment;(4)pregnant or plan to be pregnant
Inclusion Criteria:

 -  Clinical diagnosis of PM/DM-ILD,RA-ILD,IPAF,IPF

 Exclusion Criteria:

 -  Combined with pulmonary infection,pulmonary tuberculosis,carsinoma.